TrialCompass™ TCL
Back to results
Not yet recruitingPriority 4 · Lower priorityNCT07409168

Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL

ClinicalTrials.gov

Plain-language summary

This study is evaluating a new treatment as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL

NCT07409168

Status: Not yet recruiting | Priority: Lower

Plain-language summary

This study is evaluating a new treatment as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: Predictive accuracy of first-line treatment response (CR vs non-CR) according to Lugano 2014 criteria

Ages: 18 Years to —

Start date: 2026-08-15 | Est. completion: 2027-12-31

Locations

0 US sites · 0 total

Contact

Qingqing Cai, MD. PhD. | caiqq@sysucc.org.cn | 0208734282

Sponsor: Sun Yat-sen University (OTHER)

Tags

ENKTL · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07409168

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.